Singh-Tan, S., Torres-Lockhart, K., Jakubowski, A., Lu, T., Starrels, J., De Lima, P., Arnsten, J., Nahvi, S., Southern, W. (2023). Addiction Consult Service and Inpatient Outcomes Among Patients with Alcohol Use Disorder. /J Gen Intern Med/, 1-8. doi:10.1007/s11606-023-08202-7
Jakukowski, A., Singh-Tan, S., Torres-Lockhart, K., Nahvi, S., Stein, M., Fox, A. D., & Lu, T. (2023). Hospital-based clinicians lack knowledge and comfort in initiating medications for opioid use disorder: opportunities for training innovation. /Addict Sci Clin Pract, 18/(1), 31. doi:10.1186/s13722-023-00386-x
Calcaterra, S. L., Bottner, R., Martin, M., Englander, H., Weinstein, Z. M., Weimer, M. B., Lambert, E., Ronan, M., Huerta, S., Zaman, T., Ullal, M., Peterkin, A., Torres-Lockhart, K., Buresh, M., O’Brien, M., Synder, H., Herzig, S. J. (2022). Management of opioid use disorder, opioid withdrawal, and opioid overdose prevention in hospitalized adults: A systematic review of existing guidelines. /J Hosp Med, 17(9),/679-692/./doi:10.1002/jhm.12908
Torres-Lockhart, K. E., Lu, T. Y., Weimer, M. B., Stein, M. R., & Cunningham, C. O. (2022). Clinical Management of Opioid Withdrawal. /Addiction, 117/(9), 2540-2550. doi:10.1111/add.15818
Cunningham, C. O., Khalid, L., Deng, Y., Torres-Lockhart, K., Masyukova, M., Thomas, S., Zhang, C., Lu, T. (2022). A comparison of office-based buprenorphine treatment outcomes in Bronx community clinics before versus during the COVID-19 pandemic. /J Subst Abuse Treat, 135/, 108641. doi:10.1016/j.jsat.2021.108641
Joseph, G., Torres-Lockhart, K., Stein, M. R., Mund, P. A., & Nahvi, S. (2021). Reimagining patient-centered care in opioid treatment programs: Lessons from the Bronx during COVID-19. /J Subst Abuse Treat, 122/, 108219. doi:10.1016/j.jsat.2020.108219
He, L., Torres-Lockhart, K., Forster, N., Ramakrishnan, S., Greninger, P., Garnett, M. J., McDermott, U., Rothenberg, S.M., Benes, C.H., Ellisen, L. W. (2013). Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma. /Cancer Discov, 3/(3), 324-337. doi:10.1158/2159-8290.CD-12-0417
Ibrahim, Y. H., Garcia-Garcia, C., Serra, V., He, L., Torres-Lockhart, K., Prat, A., Anton, P., Cozar, P., Guzman, M., Grueso, J., Rodriguez, O., Calvo, M.T., Aura, C., Diez, O., Rubio, I.T., Perez, J., Rodon, J., Cortes, J., Ellisen, L.W., Scaltriti, M., Baselga, J. (2012). PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. /Cancer Discov, 2/(11), 1036-1047. doi:10.1158/2159-8290.CD-11-0348